gemtuzumab ozogamicina - rezultati pretrage

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

estrela 0,56 mg/1 kapsula kapsula, tvrda

proton med d.o.o. banja luka - финголимод - kapsula, tvrda - 0,56 mg/1 kapsula - 1 kapsula, tvrda sadrži: 0,5 mg fingolimoda (u obliku 0,56 mg fingolimod hidrohlorida)

fingolimod pharmascience 0,5 mg/1 kapsula kapsula, tvrda

evropa lijek pharma d.o.o. - финголимод - kapsula, tvrda - 0,5 mg/1 kapsula - jedna kapsula, tvrda sadrži: 0,5 mg fingolimoda (u obliku fingolomid hidrohlorida)

mayzent 0,25 mg/1 tableta filmom obložena tableta

novartis ba d.o.o. - siponimod - filmom obložena tableta - 0,25 mg/1 tableta - jedna filmom obložena tableta sadrži: 0,25 mg siponimoda u obliku siponimod fumaratne kiseline

mayzent 0,25 mg/1 tableta filmom obložena tableta

novartis ba d.o.o. - siponimod - filmom obložena tableta - 0,25 mg/1 tableta - jedna filmom obložena tableta sadrži: 0,25 mg siponimoda u obliku siponimod fumaratne kiseline

mayzent 2 mg/1 tableta filmom obložena tableta

novartis ba d.o.o. - siponimod - filmom obložena tableta - 2 mg/1 tableta - jedna filmom obložena tableta sadrži: 2 mg siponimoda u obliku siponimod fumaratne kiseline

Europska Unija - hrvatski - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - multipla skleroza - selektivni imunosupresivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

tysabri 300 mg/15 ml koncentrat za rastvor za infuziju

medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba

Europska Unija - hrvatski - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Europska Unija - hrvatski - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hidroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunosupresivi - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

mavenclad 10 mg/1 tableta tableta

glosarij cd d.o.o. sarajevo - kladribin - tableta - 10 mg/1 tableta - 1 tableta sadrži: 10 mg kladribina